UA122040U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method for diagnosing the development of atherosclerosis includes clinical examination, studies of low and high density lipoprotein cholesterol levels, arteriography, determination of MTHFR C677T gene polymorphism in serum, thrombomodulin content, folic acid, SICR, IL-6. With homozygous carrier 677-TT, thrombomodulin levels> 5 ng / ml, folic acid <6 ng / ml, CISP <102 ng / ml, IL-6> 10 ng / l, homocysteine> 20 μmol / l diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (Okorokov A.N.

Diagnosis of diseases of internal organs. - Vol. 6 - pp. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that, along with the study of low and high-density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of thrombomodulin, folic acid, C-terminal propeptide of type I collagen (SICP), interleukin 6 (IL-b), homocysteine. At a homozygous carrier of 677-TT, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SSRI "102 ng/ml, IL-6 "10 ng/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

Application of the method

During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. The polymorphism of the MTNEK C677T gene is determined in the patient's blood serum. The content of thrombomodulin, folic acid, SISR, IL-b6, and homocysteine is determined by the immunoenzymatic method. At a homozygous carrier of 677-TT, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SSRI "102 ng/ml, IL-6 "10 ng/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

A specific example of using the method.

Patient 3., 39 years old, was hospitalized with a diagnosis of rheumatoid arthritis. Inspected.

Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. There are no signs of atherosclerosis. The MTNEK gene polymorphism was determined in blood serum

From p677tT. The immunoenzymatic method determined the content of thrombomodulin, folic acid, SISR,

IL-6, homocysteine. Homozygous carrier 677-TT was established. Levels of thrombomodulin - 12 ng/ml, folic acid - 3 ng/ml, SISR - 80 ng/ml, IL-6-20 ng/l, homocysteine - 34 μmol/l.

The development of atherosclerosis was diagnosed. Arteriographic signs of atherosclerosis were established only after 12 months.

Thus, the proposed method allows diagnosing atherosclerosis in the early stages of the process.

Claims (1)

USEFUL MODEL FORMULA 40 The method of diagnosing the development of atherosclerosis, which includes a clinical examination, a study of low and high-density lipoprotein cholesterol levels, arteriography, determination of the MTNEV C677T gene polymorphism, the content of thrombomodulin, folic acid, SISR, IL-b, and homocysteine in blood serum, which is distinguished by the fact that with homozygous carrier 677-YIT, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SSRI "102 ng/ml, IL-b "10 ng/l, 45 homocysteine 220 μmol/l diagnoses the development of atherosclerosis.